Physician profile
Bruce D Barton
NPI 1104005925
$7,033.30
in general payments reported to CMS, 2019-2025
42 companies · $24.05 in 2025
The $24.05 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $896 · 2021: $2,121 · 2022: $1,991 · 2023: $1,387 · 2025: $24.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,158.85 | 2021-2023 | Qulipta, Ubrelvy, Botox |
| Amgen INC. | $858.03 | 2019-2023 | Aimovig |
| Novartis Pharmaceuticals Corporation | $833.65 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $600.49 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $518.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $448.12 | 2020-2023 | Ajovy |
| Genzyme Corporation | $411.13 | 2019-2023 | |
| Allergan, INC. | $214.18 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $190.00 | 2020-2023 | |
| Pfizer INC. | $180.66 | 2023 | |
| Janssen Pharmaceuticals, INC | $161.75 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $139.84 | 2020-2021 | |
| Biogen, INC. | $137.86 | 2020-2023 | Vumerity, Tysabri, Plegridy |
| Supernus Pharmaceuticals, INC. | $128.39 | 2019-2022 | |
| Almatica Pharma LLC | $125.73 | 2022-2023 | Gralise |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.